Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QGEN Stock Forecast 2026-2027
$41.04
Current Price
$8.50B
Market Cap
Buy 7
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to QGEN Price Targets
+51.1%
To High Target of $62.00
+30.4%
To Median Target of $53.50
+7.2%
To Low Target of $44.00
QGEN Price Momentum
-1.7%
1 Week Change
+2.8%
1 Month Change
+1.4%
1 Year Change
-13.3%
Year-to-Date Change
-29.0%
From 52W High of $57.82
+5.8%
From 52W Low of $38.80
📊 TOP ANALYST CALLS
Did QGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if QIAGEN is one of their latest high-conviction picks.
Latest QGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, QGEN has a neutral consensus with a median price target of $53.50 (ranging from $44.00 to $62.00). The overall analyst rating is Buy (7.4/10). Currently trading at $41.04, the median forecast implies a 30.4% upside. This outlook is supported by 7 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 51.1% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 7.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QGEN Analyst Ratings
7
Buy
9
Hold
0
Sell
QGEN Price Target Range
Low
$44.00
Average
$53.50
High
$62.00
Current: $41.04
Latest QGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Barclays | Luke Sergott | Equal-Weight | Downgrade | $44.00 |
| Mar 13, 2026 | Deutsche Bank | Jan Koch | Buy | Upgrade | $54.00 |
| Feb 6, 2026 | JP Morgan | Casey Woodring | Overweight | Maintains | $60.00 |
| Feb 6, 2026 | Stifel | Daniel Arias | Hold | Maintains | $50.00 |
| Feb 6, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $55.00 |
| Jan 22, 2026 | Deutsche Bank | Jan Koch | Hold | Downgrade | $54.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $55.00 |
| Dec 11, 2025 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $50.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $53.00 |
| Aug 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $50.00 |
| Jun 26, 2025 | B of A Securities | Derik De Bruin | Buy | Maintains | $53.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $55.00 |
| Apr 21, 2025 | Baird | Catherine Schulte | Neutral | Maintains | $43.00 |
| Apr 4, 2025 | Redburn Atlantic | Ed Ridley-Day | Neutral | Downgrade | $N/A |
| Feb 19, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $42.00 |
| Feb 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $48.00 |
| Jan 6, 2025 | Morgan Stanley | Steve Beuchaw | Equal-Weight | Downgrade | $48.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Upgrade | $54.00 |
| Oct 17, 2024 | HSBC | Shubhangi Gupta | Hold | Downgrade | $N/A |
| Aug 2, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $52.00 |
QIAGEN N.V. (QGEN) Competitors
The following stocks are similar to QIAGEN based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QIAGEN N.V. (QGEN) Financial Data
QIAGEN N.V. has a market capitalization of $8.50B with a P/E ratio of 20.1x. The company generates $2.09B in trailing twelve-month revenue with a 20.3% profit margin.
Revenue growth is +3.7% quarter-over-quarter, while maintaining an operating margin of +27.4% and return on equity of +11.6%.
Valuation Metrics
Market Cap
$8.50B
Enterprise Value
$9.23B
P/E Ratio
20.1x
PEG Ratio
0.9x
Price/Sales
4.0x
Growth & Margins
Revenue Growth (YoY)
+3.7%
Gross Margin
+60.2%
Operating Margin
+27.4%
Net Margin
+20.3%
EPS Growth
+22.1%
Financial Health
Cash/Price Ratio
+13.0%
Current Ratio
3.9x
Debt/Equity
48.6x
ROE
+11.6%
ROA
+5.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
QIAGEN N.V. (QGEN) Business Model
About QIAGEN N.V.
What They Do
Provides solutions for biological sample analysis.
Business Model
The company operates on a business model that focuses on providing Sample to Insight solutions, converting biological samples into molecular insights. It generates revenue through the sale of over 500 core products, including disposable kits, automated workstations, and testing agents, primarily to sectors such as healthcare, forensics, veterinary, and research.
Additional Information
Founded in 1984 and headquartered in the Netherlands, QIAGEN serves more than 500,000 customers globally, operating in over 130 countries. The company is led by CEO Thierry Bernard and has a strong track record of acquisitions that enhance its diagnostic and bioinformatics capabilities, contributing significantly to advancements in scientific research and personalized medicine.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
5,654
CEO
Mr. Thierry Bernard
Country
Netherlands
IPO Year
1996
Website
www.qiagen.comQIAGEN N.V. (QGEN) Latest News & Analysis
Latest News
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
6 days ago
Quick Summary
QIAGEN N.V. announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infections, coinciding with the ESCMID Global Congress in Munich.
Why It Matters
QIAGEN's launch of a new testing panel for bloodstream infections enhances its product line, potentially increasing market share and revenue, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
4 days ago
Quick Summary
QIAGEN N.V. will present its oncology workflow applications at the AACR Annual Meeting 2026, highlighting its multi-omics profiling and genomic data interpretation capabilities for cancer research.
Why It Matters
QIAGEN's showcase at a major cancer research conference highlights its innovation in oncology, signaling potential growth in the diagnostics market, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Parse Biosciences, a QIAGEN company, has launched Evercode™ Whole Transcriptome FFPE kits for single-cell RNA sequencing from formalin-fixed samples, now available for researchers.
Why It Matters
The launch of Evercode™ Whole Transcriptome FFPE kits enhances Parse Biosciences' product portfolio, potentially increasing revenue and market share in the growing single-cell sequencing market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
QIAGEN N.V. (NYSE: QGEN) has filed its annual report and audited financial statements for the year ended December 31, 2025, with the SEC. The report is available on its website.
Why It Matters
QIAGEN's filing of its annual report signals transparency and compliance with regulatory requirements, potentially influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
1 month ago
Quick Summary
QIAGEN N.V. (NYSE: QGEN) announced new data supporting its QuantiFERON-TB Gold Plus test for tuberculosis detection, particularly in high-risk populations, ahead of World TB Day.
Why It Matters
The announcement of new clinical data for QIAGEN's TB test enhances its market positioning and potential revenue growth, especially in high-risk populations, impacting investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Qiagen N.V. (QGEN) recently presented at the Leerink Global Healthcare Conference 2026, discussing company updates and future prospects.
Why It Matters
Qiagen's presentation at a prominent healthcare conference signals potential growth opportunities and investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About QGEN Stock
What is QIAGEN N.V.'s (QGEN) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, QIAGEN N.V. (QGEN) has a median price target of $53.50. The highest price target is $62.00 and the lowest is $44.00.
Is QGEN stock a good investment in 2026?
According to current analyst ratings, QGEN has 7 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QGEN stock?
Wall Street analysts predict QGEN stock could reach $53.50 in the next 12 months. This represents a 30.4% increase from the current price of $41.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is QIAGEN N.V.'s business model?
The company operates on a business model that focuses on providing Sample to Insight solutions, converting biological samples into molecular insights. It generates revenue through the sale of over 500 core products, including disposable kits, automated workstations, and testing agents, primarily to sectors such as healthcare, forensics, veterinary, and research.
What is the highest forecasted price for QGEN QIAGEN N.V.?
The highest price target for QGEN is $62.00 from Patrick Donnelly at Citigroup, which represents a 51.1% increase from the current price of $41.04.
What is the lowest forecasted price for QGEN QIAGEN N.V.?
The lowest price target for QGEN is $44.00 from Luke Sergott at Barclays, which represents a 7.2% increase from the current price of $41.04.
What is the overall QGEN consensus from analysts for QIAGEN N.V.?
The overall analyst consensus for QGEN is neutral. Out of 20 Wall Street analysts, 7 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $53.50.
How accurate are QGEN stock price projections?
Stock price projections, including those for QIAGEN N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 3:43 AM UTC